Sat.Jun 18, 2022 - Fri.Jun 24, 2022

article thumbnail

Pharmacy Should be ‘Special’ for All Patients

Pharmacy Times

Even if the financial resources were available, there aren’t enough human resources in pharmacy to provide high-touch engagement to the millions of patients who suffer from common chronic diseases.

181
181
article thumbnail

Five Common Financial Mistakes To Avoid As A Pharmacist

IDStewardship

In this article a pharmacist with significant experience in the area of finance identifies and discusses five common financial mistakes to avoid as a pharmacist. . Authored By: Timothy Ulbrich, PharmD. Co-Founder and CEO of Your Financial Pharmacist (YFP). Article posted 21 June 2022. While financial mistakes may seem inevitable, some do not have to be.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Greece slaps Novartis with €214 million bribery suit

European Pharmaceutical Review

The Greek state has filed a lawsuit against Novartis , asking for € 214 million in compensation for non-pecuniary damages* the country may have suffered due to alleged illegal payments to government officials and healthcare providers. Commenting on the lawsuit , Greece’s Health Minister Thanos Plevris, stated that the country is seeking compensation for the damage it has suffered “from the actions that Novartis itself has admitted to in the USA that concerns payments to doctors.”.

138
138
article thumbnail

Eisai’s brain health tool NouKNOW used in Tokyo dementia project

pharmaphorum

Eisai’s digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed at improving the management of dementia. The smartphone app – which uses a cognition-checking algorithm developed by Australian digital health company Cogstate – will be deployed in Bunkyo City, Tokyo in a dementia monitoring programme.

137
137
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

USP Expert: It’s Critical Pharmacists Have Conversations With Patients on Adherence, Storage Issues That Result in Antimicrobial Resistance

Pharmacy Times

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

172
172
article thumbnail

'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

PharmaVoice

The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

More Trending

article thumbnail

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

pharmaphorum

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly’s Verzenios, after new guidance from NICE backed use of the drug after surgery for early-stage tumours. The new advice means that around 4,000 people with hormone receptor-positive, HER2-negative, node-positive early breast cancer who are considered at high risk of recurrence after surgery can receive Verzenios (abemaciclib) in combination with standard hormone therapy, said the

116
116
article thumbnail

Pandemic Created Combat Like Trauma for Pharmacists

Pharmacy Times

The impact of the pandemic on the mental health of health care workers, including pharmacists and pharmacy staff, has been well documented.

article thumbnail

Covid-19 vaccines targeting Omicron variants expected to be ready for this autumn

Pharmaceutical Technology

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. In addition to providing protection against the Omicron BA.1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4 and BA.5.

Vaccines 105
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. It is an exciting year… but whether the changes will be a net positive or a net negative is yet to be seen” Maarten Meulenbelt, Partner, Sidley Austin LLP. 2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

pharmaphorum

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of the disease transthyretin amyloidosis (ATTR) it licensed from Ionis in a $3.6 billion deal last year. Eplontersen – previously known as IONIS-TTR-LRX – is designed to switch off the production of transthyretin (TTR), a protein which builds up in the disease to toxic levels causing heart problems (cardiomyopathy) and nerve damage (polyneuropathy).

FDA 111
article thumbnail

Oncology Overview: Abemaciclib, a CDK4/6 Inhibitor for Prostate Cancer

Pharmacy Times

Abemaciclib (Verzenio; Eli Lilly and Company) is an FDA-approved kinase inhibitor being investigated for new indications in individuals with hormone-sensitive prostate cancer and castration-resistant prostate cancer.

FDA 149
article thumbnail

EC approves Novartis’ Tabrecta for non-small cell lung cancer

Pharmaceutical Technology

The European Commission (EC) has approved Novartis’ Tabrecta (capmatinib) as a monotherapy to treat advanced non-small cell lung cancer (NSCLC) in adults. The treatment is intended for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping and for those who need systemic therapy after previous treatment with immunotherapy and/or platinum-based chemotherapy.

article thumbnail

Benefits of PCD Pharma Company

Fossil Remedies

If you see the growth pattern of the Indian economy, then it has been tremendous. The country has done remarkably well and despite the setback after the pandemic, it is roaring high with full speed. All sector of the Indian economy has done good, but the pharma sector is doing exceptionally well. It is among the fastest-growing sectors in India. Since there is an opportunity to earn, every dynamic business owner wants to reap benefits from that.

91
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

US frets over pharma supply chain security

pharmaphorum

The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out. Ben Hargreaves finds out how the issue of foreign manufacturing has become a major US political talking point and how this could influence the pressures facing the industry. In a global economy, across a number of industries, low-margin products are often manufactured in countries where labour is cheap.

article thumbnail

The Impact of COVID-19 on Cervical, Breast Cancer Screenings

Pharmacy Times

Breast cancer screening guidelines using mammography vary among guiding bodies, including the American Cancer Society and the American Academy of Family Physicians.

153
153
article thumbnail

Novavax’s Covid-19 vaccine gets Taiwan FDA EUA for use in adults

Pharmaceutical Technology

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-

Vaccines 105
article thumbnail

HistoSonics hits enrollment target en route to FDA filing for liver cancer therapy

Outsourcing Pharma

The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.

FDA 98
article thumbnail

Is Merck planning a $30bn-plus move for Seagen?

pharmaphorum

Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community aflutter. The rumour was first published in the Wall Street Journal, which suggests that a takeover is just one option on the table, along with a marketing deal that would bind the two companies together without the risk of antitrust issues holding up or blocking a merger.

105
105
article thumbnail

Study: Herpes Zoster Is Not Associated With Increased Risk of Dementia

Pharmacy Times

But investigators find that individuals who had shingles that spread to the central nervous system had nearly twice the risk of developing mental deterioration, though it is rare.

139
139
article thumbnail

BioNTech launches African vaccine production in Rwanda

European Pharmaceutical Review

BioNTech has initiated construction of its first vaccine production facility in Africa. Located in Kigali, Rwanda, the mRNA manufacturing facility will be the first of three planned sites across the continent, with further factories to come in Senegal and South Africa. Together this network of factories will supply therapies and vaccines solely for people residing in member states of the African Union.

article thumbnail

BIO research outlines risks in changing accelerated approval pathway

Outsourcing Pharma

If new restrictions are placed on the FDAâs Accelerated Approval pathway, as many as two thirds of the treatments that use this pathway would never reach patients, according to research released at the BIO International Convention last week.

69
article thumbnail

Pfizer is first big pharma to tap Truveta’s real-world data platform

pharmaphorum

Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of safety and other signals for its products, including COVID-19 vaccine Comirnaty, almost in real-time. Truveta’s platform is based on electronic medical record data – updated daily – for more than 50 million people in the US, harvesting anonymised patient care information from tens of thousands of clinical care sites across 42 states.

article thumbnail

Calling Them “Vanity Drugs,” Some Insurers Refuse to Cover New Anti-Obesity Drugs

Pharmacy Times

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Insurance 164
article thumbnail

#DIA2022: How the industry's top regulator views the future of healthcare

PharmaVoice

In the evolution of healthcare, data is the linchpin to making drug development more efficient.

97
article thumbnail

invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m

Pharmaceutical Technology

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 for each share in cash. invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. The latest deal will expedite the strategy of invoX to develop the International Biopharmaceutical R&D Platform of Sino Biopharm outside of China to transform the lives of patients globally.

article thumbnail

Pfizer takes stake in French Lyme disease jab partner Valneva

pharmaphorum

Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of their alliance to develop a shot for Lyme disease. The deal gives Valneva a cash injection that it will be able to use to advance Lyme disease candidate VLA15 towards the market, but the revised licensing terms means that the French biotech will shoulder more of the financial cost of the development programme.

article thumbnail

ONE Program Aims to Break Stigma of Opioid Use, Save More Patient Lives

Pharmacy Times

The Opioid and Naloxone program at North Dakota State University School of Pharmacy aims to make a difference.

171
171
article thumbnail

epocrates Appoints New Leaders to Guide Commercial Strategy, Consulting, and Customer Experience

PharmExec

Additions of Andrew Johnson and Bridget Seay strengthen epocrates’ evolution as a commercial organization with best-in-class market intelligence and products.

75
article thumbnail

Non-stop investment from CMOs and US Government into continuous manufacturing

Pharmaceutical Technology

In the last year, well-known contract manufacturing organisations (CMOs) such as Agilent Technologies (Santa Clara, California) and Abzena (Cambridge, UK) have expanded their continuous manufacturing capabilities. US Congress is also making substantial investments to improve the continuous manufacturing of pharmaceuticals. As more drugs are approved with continuous manufacturing, this production method is becoming increasingly mainstream.

FDA 64
article thumbnail

IP is no barrier to COVID vaccine access, says industry

pharmaphorum

While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their populations, the pharma industry has called the proposals “unnecessary and harmful to innovation”. Proposals to waive COVID-19 product patents have been described as “political posturing” and an “answer to a problem that does not exist”.

article thumbnail

FDA Approves Expanded Indication for Vaxneuvance Pneumococcal Vaccine

Pharmacy Times

Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.

Vaccines 132
article thumbnail

The benefits of in-person meetings for pharmaceutical microbiology

Pharmig

We’ve all become incredibly familiar with the various online platforms that have facilitated all of us staying in contact and being able to run organisations and businesses throughout the global pandemic. The post The benefits of in-person meetings for pharmaceutical microbiology appeared first on Pharmig.

52
article thumbnail

BioMarin’s Voxzogo obtains Japan’s MHLW approval for achondroplasia

Pharmaceutical Technology

BioMarin Pharmaceutical has obtained Japan’s Ministry of Health, Labor and Welfare (MHLW) approval of the registration for its Voxzogo (vosoritide) for injection to treat achondroplasia in children whose growth plates are not closed. A modified C-type natriuretic peptide (CNP), Voxzogo acts on achondroplasia’s underlying pathophysiology. It works by down-regulating fibroblast growth factor receptor 3 (FGFR3) signalling and subsequently boosting endochondral bone formation.

64